Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer
Jitsuo Usuda, Yoshihiko Tsunoda, Shuji Ichinose, Taichirou Ishizumi, Keishi Ohtani, Sachio Maehara, Shoutarou Ono, Hidemitsu Tsutsui, Tatsuo Ohira, Tetsuya Okunaka, Kinya Furukawa, Yoshikazu Sugimoto, Harubumi Kato, Norihiko Ikeda
20100101
2010 Feb 1
Lung Cancer
Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer
Lung Cancer. 2010 Feb;67(2):198-204, Jitsuo Usuda, Yoshihiko Tsunoda, Shuji Ichinose, Taichirou Ishizumi, Keishi Ohtani, Sachio Maehara, Shoutarou Ono, Hidemitsu Tsutsui, Tatsuo Ohira, Tetsuya Okunaka, Kinya Furukawa, Yoshikazu Sugimoto, Harubumi Kato, Norihiko Ikeda
The ATP-binding cassette (ABC) transporter protein, BCRP (breast cancer resistance protein)/ABCG2 pumps out some types of photosensitizers used in photodynamic therapy (PDT) and causes resistance to the antitumor effect of PDT. The purpose of this study was to investigate the association between the expression of BCRP and the efficacy of PDT using Photofrin, or the second-generation photosensitizer, NPe6, for centrally located early lung cancers.Using human epidermoid carcinoma cells, A431 cells...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
